Results 71 to 80 of about 7,539 (166)

Human Visceral Leishmaniasis in Kermanshah Province, Western Iran, During 2011-2012

Iranian Journal of Parasitology, 2012
Background: Visceral leishmaniasis (VL) or kala-azar is a parasitic disease caused by the species of Leishmania donovani complex. It is endemic in some parts of provinces of Iran.
H Bashiri, K Ghadiri, N Khademi, B Akhoundi, M Mohebali, B Hamzeh, Y Hamzavi, M Pajhouhan   +7 more
doaj  

Human Visceral Leishmaniasis in Kermanshah Province, Western Iran, During 2011-2012

Iranian Journal of Parasitology, 2015
Background: Visceral leishmaniasis (VL) or kala-azar is a parasitic disease caused by the species of Leishmania donovani complex. It is endemic in some parts of provinces of Iran.
Y. Hamzavi, B. Hamzeh, M. Mohebali, B. Akhoundi, KH. Ajhang, N. Khademi, K. Ghadiri, H. Bashiri, M. Pajhouhan   +8 more
doaj  

Serological Study of Visceral Leishmaniasis in Boyer Ahmad Township in 2005

Armaghane Danesh Bimonthly Journal, 2007
Introduction & Objective: Visceral leishmaniasis (Kala-azar) is a disease caused by intracellular protozoa parasites of the genus Leishmania. Kala–azar in Iran is usually seen in children below 10 years old.
B Sarkari, AA Moshfe, N Pedram, MA Zargar, B Yazdanpanah, B Akhondi, Z Hasani, M Mohebali   +7 more
doaj  

Evaluation and comparison of indirect immunofluorescent antibodytest (IFAT) and Direct agglutination test (DAT) using standardized antigen in diagnosis of visceral leishmaniasis

Journal of Mazandaran University of Medical Sciences, 2005
Background and purpose : Human visceral leishmaniasis (HVL) is endemic in several foci in IRAN, such as Ardebil and Fars provinces (in North western and southern parts of IRAN) and in some regions as sporadic.
M. Ghasemi, H. Hejaziv, D. Dorostkar Moghaddam   +2 more
doaj  

Kala-Azar: A Case Report. [PDF]

Cureus, 2023
Jancar N, Sousa Gonçalves F, Duro J, Pinto I, Oliveira T, Aguiar P.   +5 more
europepmc   +1 more source

Evaluation of Recombinase Polymerase Amplification assay for monitoring parasite load in patients with kala-azar and post kala-azar dermal leishmaniasis. [PDF]

PLoS Negl Trop Dis, 2023
Roy M, Ceruti A, Kobialka RM, Roy S, Sarkar D, Wahed AAE, Chatterjee M.   +6 more
europepmc   +1 more source

Risk factors for post-kala-azar dermal leishmaniasis (PKDL): Challenges in understanding pathophysiology. [PDF]

PLoS Negl Trop Dis
Zijlstra EE.
europepmc   +1 more source

Safety and Effectiveness of Miltefosine in Post-Kala-Azar Dermal Leishmaniasis: An Observational Study. [PDF]

Open Forum Infect Dis, 2023
Sundar S, Singh J, Dinkar A, Agrawal N.
europepmc   +1 more source

Report of the Seventh Post-Kala-Azar Dermal Leishmaniasis Consortium meeting, Kolkata, India, 28-29 November 2024. [PDF]

Parasit Vectors
Chatterjee M, Sengupta R, Cloots K, Zijlstra EE.   +3 more
europepmc   +1 more source

Para Kala-Azar Dermal Leishmaniasis: A Case Report. [PDF]

Cureus, 2023
Moniruzzaman M, Been Sayeed SKJ, Rahim MA, Hassan R, Rahman MM.   +4 more
europepmc   +1 more source